Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Celldex Therapeutics (CLDX) EBIT (2016 - 2025)

Historic EBIT for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to -$73.6 million.

  • Celldex Therapeutics' EBIT fell 4122.89% to -$73.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$256.2 million, marking a year-over-year decrease of 3726.31%. This contributed to the annual value of -$195.1 million for FY2024, which is 2622.98% down from last year.
  • According to the latest figures from Q3 2025, Celldex Therapeutics' EBIT is -$73.6 million, which was down 4122.89% from -$63.9 million recorded in Q2 2025.
  • In the past 5 years, Celldex Therapeutics' EBIT ranged from a high of -$13.4 million in Q2 2021 and a low of -$73.6 million during Q3 2025
  • Moreover, its 5-year median value for EBIT was -$36.4 million (2022), whereas its average is -$38.8 million.
  • Its EBIT has fluctuated over the past 5 years, first surged by 1792.1% in 2021, then plummeted by 17080.36% in 2022.
  • Over the past 5 years, Celldex Therapeutics' EBIT (Quarter) stood at -$20.3 million in 2021, then tumbled by 37.09% to -$27.9 million in 2022, then crashed by 70.8% to -$47.6 million in 2023, then dropped by 17.64% to -$56.0 million in 2024, then tumbled by 31.4% to -$73.6 million in 2025.
  • Its EBIT was -$73.6 million in Q3 2025, compared to -$63.9 million in Q2 2025 and -$62.7 million in Q1 2025.